Opus Genetics, Inc. (IRD) return on equity (ROE)

Return on equity · fiscal 2025
-323.1%

Opus Genetics, Inc. (IRD) earned a return on equity of -323.1% in fiscal 2025 (the year ended December 31, 2025). That is 532.5 percentage points higher than the -855.6% of fiscal 2024. Figures as of 18 Nov 2026, 10:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-323.1%
Change on fiscal 2024
+532.5 pts
Highest on record
38.7%fiscal 2022
Lowest on record
-855.6%fiscal 2024
Fiscal years on record
192002–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Opus Genetics, Inc. return on equity (ROE), in more detail

Across the 19 fiscal years on record (2002–2025), the highest was 38.7% in fiscal 2022 and the lowest -855.6% in fiscal 2024. The fiscal 2025 figure is higher than in 11% of the 18 earlier fiscal years on record, whose median is -91.3%.

History · 19 fiscal years

Return on equity by fiscal year

Opus Genetics, Inc. return on equity (ROE), year by year

Opus Genetics, Inc. (IRD) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-323.1% 532.5 pts up
2024-855.6% 835.6 pts down
2023-20.0% 58.7 pts down
202238.7% 293.8 pts up
2021-255.1%—
2017-150.8% 96.3 pts down
2016-54.6% 22.1 pts up
2015-76.6% 6.9 pts down
2014-69.7% 5.6 pts up
2013-75.2% 9.9 pts down
2012-65.3% 40.7 pts up
2011-106.0% 28.9 pts up
2010-134.9% 75.7 pts down
2009-59.2%—
2007-463.6% 261.8 pts down
2006-201.8% 70.3 pts down
2005-131.5%—
2003-112.0% 68.5 pts down
2002-43.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on IRD

Opus Genetics, Inc., figure by figure

Opus Genetics, Inc. (IRD) overview: price, valuation and scorecard

Opus Genetics, Inc. return on equity (ROE): questions and answers

What is Opus Genetics, Inc.'s return on equity?

Opus Genetics, Inc. (IRD) earned a return on equity of -323.1% in fiscal 2025 (the year ended December 31, 2025). That is 532.5 percentage points higher than the -855.6% of fiscal 2024.

Is Opus Genetics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 11% of the 18 earlier fiscal years on record, whose median is -91.3%.

What are the highest and lowest return on equity figures on record for Opus Genetics, Inc.?

Across the 19 fiscal years on record (2002–2025), the highest was 38.7% in fiscal 2022 and the lowest -855.6% in fiscal 2024.

How is Opus Genetics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Opus Genetics, Inc. it is on record here for 19 fiscal years, 2002 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Opus Genetics, Inc. (IRD) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/IRD/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.